Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: New insights and implications for therapy

Annals of the New York Academy of Sciences

Volumn 1122, Issue , 2007, Pages 155-168

  Weinreb, Orly ^a   Amit, Tamar ^a   Bar Am, Orit ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Alzheimer's disease; BDNF; GDNF; Neuroprotection neurorescue; Neurorestoration; Neurotrophic factors; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LADOSTIGIL; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; RASAGILINE;

ALZHEIMER DISEASE; AMNESIA; CHEMICAL STRUCTURE; CONFERENCE PAPER; DEGENERATIVE DISEASE; DEMENTIA; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; TREATMENT DURATION;

ANIMALIA;

EID: 37049015753     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1403.011     Document Type: Conference Paper

References (77)

1. MCALLISTER, A.K. 2001. Neurotrophins and neuronal differentiation in the central nervous system. Cell Mol. Life Sci. 58: 1054-1060.
2. MURER, M.G., Q. YAN & R. RAISMAN- VOZARI. 2001. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 63: 71-124.
3. SIEGEL, G.J. & N.B. CHAUHAN. 2000. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Brain Res. Rev. 33: 199-227.
4. SHEN, L., A. FIGUROV & B. LU. 1997. Recent progress in studies of neurotrophic factors and their clinical implications. J. Mol. Med. 75: 637-644.
5. FRIEDMAN, W.J. & L.A. GREENE. 1999. Neurotrophin signaling via Trks and p75. Exp. Cell Res. 253: 131-142.
6. SEGAL, R.A. & M.E. GREENBERG. 1996. Intracellular signaling pathways activated by neurotrophic factors. Annu. Rev. Neurosci. 19: 463-489.
7. MURAKAMI, H. et al. 1999. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem. Biophys. Res. Commun. 262: 68-75.
8. CHAUHAN, N.B., G.J. SIEGEL & J.M. LEE. 2001. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J. Chem. Neuroanat. 21: 277-288.
9. LAD, S.P., K.E. NEET & E.J. MUFSON. 2003. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 2: 315-334.
10. HOLSINGER, R.M. et al. 2000. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res. Mol. Brain Res. 76: 347-354.
11. MURRAY, K.D. et al. 1994. Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer's disease. Neuroscience 60: 37-48.
12. NISHIMURA, M. et al. 2005. Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy. Mov. Disord. 20: 1031-1033.
13. COMBARROS, O. et al. 2004. Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 18: 55-58.
14. GROUP, P.S. 2004. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61: 561-566.
15. GROUP, P.S. 2005.Arandomized placebo-controlled trial of rasagiline in levodopatreated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62: 241-248.
16. SAGI, Y. et al. 2007. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25: 35-44.
17. WEINREB, O. et al. 2005. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann. N. Y. Acad. Sci. 1053: 348-355.
18. YOGEV-FALACH, M. et al. 2003. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J. 17: 2325-2327.
19. BAR-AM, O. et al. 2005. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 19: 1899-1901.
20. MARUYAMA, W., M. NAOI & M.B.H. YOUDIM. 2000. Propargylamines protect dopamine cells from apoptosis induced by a neurotoxin, N-Methyl (R) salsolinol. In Neuromelanin May Mediate Neurotoxicity via its Interaction with Redox Active Iron. A. Storch & M.A. Gollins, Eds.: 321. Kluwer Academic/Plenum Publishers. New York.
21. YOUDIM, M.B.H. et al. 2003.Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. Ann. N. Y. Acad Sci. 993: 378-386.
22. YOGEV-FALACH, M. et al. 2006. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J. 20: 2177-2179.
23. WEINSTOCK, M. et al. 2003. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27: 555-561.
24. FRIM, D.M. et al. 1994. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. USA 91: 5104-5108.
25. SPINA, M.B. et al. 1992. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59: 99-106.
26. SINCLAIR, S.R. et al. 1996. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 7: 2547-2552.
27. TOMAC, A. et al. 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335-339.
28. KNUSEL, B. et al. 1992. Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J. Neurosci. 12: 4391-4402.
29. HOGLINGER, G.U. et al. 2001. Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease. Exp. Neurol. 167: 148-157.
30. FURUKAWA, K. et al. 1998. Presenilin-1 mutation alters NGF-induced neurite outgrowth, calcium homeostasis, and transcription factor (AP-1) activation in PC12 cells. J. Neurosci. Res. 52: 618-624.
31. WINDISCH, M., A. GSCHANES & B. HUTTER- PAIER. 1998. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J. Neural Transm. Suppl. 53: 289-298.
32. ERIKSDOTTER JONHAGEN, M. et al. 1998. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9: 246-257.
33. LARSEN, K.E. et al. 2006. A glial cell line-derived neurotrophic factor (GDNF): tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice. Brain Res. 1120: 1-12.
34. IBANEZ, C.F., T. EBENDAL & H. PERSSON. 1991. Chimeric molecules with multiple neurotrophic activities reveal structural elements determining the specificities of NGF and BDNF. EMBO J. 10: 2105-2110.
35. PARDRIDGE, W.M. 2002. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv. Exp. Med. Biol. 513: 397-430.
36. TOBIAS, C.A. et al. 2005. Alginate encapsulated BDNF-producing fibroblast grafts permit recovery of function after spinal cord injury in the absence of immune suppression. J. Neurotrauma 22: 138-156.
37. GAGE, F.H. et al. 1990. Gene therapy in the CNS: intracerebral grafting of genetically modified cells. Prog. Brain Res. 86: 205-217.
38. SALVATORE, M.F. et al. 2006. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp. Neurol. 202: 497-505.
39. BAI, O. et al. 2003. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 71: 127-131.
40. ALTIERI, M. et al. 2004. Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment. Brain Res. 1000: 148-155.
41. CHUN, H.S., J.J. SON & J.H. SON. 2000. Identification of potential compounds promoting BDNF production in nigral dopaminergic neurons: clinical implication in Parkinson's disease. Neuroreport 11: 511-514.
42. WEINREB, O. et al. 2004. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 18: 1471-1473.
43. MARUYAMA, W. et al. 2004. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem. Int. 44: 393-400.
44. MIZUTA, I. et al. 2000. Selegiline and desmethylselegiline stimulate NGF, BDNF, andGDNFsynthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 279: 751-755.
45. BIGLAN, K.M. et al. 2006. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov. Disord. 21: 616-623.
46. CHEN, J.J. & D.M. SWOPE. 2005. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. 45: 878-894.
47. MARUYAMA, W., M.B.H. YOUDIM & M. NAOI. 2001. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)- aminoindan, and its optical (S)-isomer, TV1022. Ann. N. Y. Acad. Sci. 939: 320-329.
48. AKAO, Y. et al. 2002. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326: 105-108.
49. MARUYAMA, W. et al. 2001. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78: 727-735.
50. AKAO, Y. et al. 2002. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82: 913-923.
51. MARUYAMA, W. et al. 2000. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm. Suppl. 60: 171-186.
52. MARUYAMA, W. et al. 2002. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24: 675-682.
53. MARUYAMA, W. et al. 2002. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109: 467-481.
54. HEIKKILA, R.E. et al. 1985. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 116: 313-317.
55. SPEISER, Z. et al. 1999. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J. Neural Transm. 106: 593-606.
56. HUANG, W. et al. 1999. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366: 127-135.
57. BAR-AM, O. et al. 2004. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem. 89: 1119-1125.
58. YOUDIM, M.B.H. et al. 2003. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective- antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem. Pharmacol. 66: 1635-1641.
59. WEINREB, O. et al. 2006. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J. Neural Transm. Suppl. 70: 457-465.
60. BLANDINI, F. 2005. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? CNS Drug Rev. 11: 183-194.
61. ZHU, Y. et al. 2004. Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1, 2 signaling pathways. Neuroscience 123: 897-906.
62. JONES, R.G. et al. 2005. NF-kappaB couples protein kinase B/Akt signaling to distinct survival pathways and the regulation of lymphocyte homeostasis in vivo. J. Immunol. 175: 3790-3799.
63. TOTH, G. et al. 2002. Gene transfer of glial cell-derived neurotrophic factor and cardiotrophin-1 protects PC12 cells from injury: involvement of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase pathways. J. Neurosci. Res. 69: 622-632.
64. WEINREB, O. et al. 2007. The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. Antioxid. Redox Signal. 9: 169-179.
65. TING, J.T., B.G. KELLEY & J.M. SULLIVAN. 2006. Synaptotagmin IV does not alter excitatory fast synaptic transmission or fusion pore kinetics in mammalian CNS neurons. J. Neurosci. 26: 372-380.
66. WEINSTOCK, M., T. GOREN & M.B.H. YOUDIM. 2000. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev. Res. 50: 216-222.
67. WEINSTOCK, M. 1999. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs 12: 307-323.
68. YOGEV-FALACH, M. et al. 2002. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 16: 1674-1676.
69. POLTYREV, T. et al. 2005. Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats. Psychopharmacology (Berl) 181: 118-125.
70. SHOHAM, S. et al. 2007. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 52: 836-843.
71. MARUYAMA, W. et al. 2003. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)- (3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. 341: 233-236.
72. GRILLI, M. et al. 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274: 1383-1385.
73. ZHENG, H. et al. 2005. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95: 68-78.
74. ZHENG, H. et al. 2005. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 13: 773-783.
75. ZECCA, L. et al. 2004. Iron, brain ageing and neurodegenerative disorders. Nature reviews. Neuroscience 5: 863-873.
76. YOUDIM, M.B. & J.J. BUCCAFUSCO. 2005. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26: 27-35.
77. AVRAMOVICH-TIROSH, Y. et al. 2007. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem. 100: 490-502.